tetano
Editor, Senior Moderator
Vaccines (Basel). 2017 Jul 18;5(3). pii: E18. doi: 10.3390/vaccines5030018.
[h=1]Egg-Independent Influenza Vaccines and Vaccine Candidates.[/h] Manini I[SUP]1[/SUP], Trombetta CM[SUP]2[/SUP], Lazzeri G[SUP]3[/SUP], Pozzi T[SUP]4[/SUP], Rossi S[SUP]5[/SUP], Montomoli E[SUP]6,[/SUP][SUP]7[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Vaccination remains the principal way to control seasonal infections and is the most effective method of reducing influenza-associated morbidity and mortality. Since the 1940s, the main method of producing influenza vaccines has been an egg-based production process. However, in the event of a pandemic, this method has a significant limitation, as the time lag from strain isolation to final dose formulation and validation is six months. Indeed, production in eggs is a relatively slow process and production yields are both unpredictable and highly variable from strain to strain. In particular, if the next influenza pandemic were to arise from an avian influenza virus, and thus reduce the egg-laying hen population, there would be a shortage of embryonated eggs available for vaccine manufacturing. Although the production of egg-derived vaccines will continue, new technological developments have generated a cell-culture-based influenza vaccine and other more recent platforms, such as synthetic influenza vaccines.
[h=4]KEYWORDS:[/h] cell-culture; synthetic influenza vaccine; vaccination
PMID: 28718786 DOI: 10.3390/vaccines5030018
Free full text
[h=1]Egg-Independent Influenza Vaccines and Vaccine Candidates.[/h] Manini I[SUP]1[/SUP], Trombetta CM[SUP]2[/SUP], Lazzeri G[SUP]3[/SUP], Pozzi T[SUP]4[/SUP], Rossi S[SUP]5[/SUP], Montomoli E[SUP]6,[/SUP][SUP]7[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Vaccination remains the principal way to control seasonal infections and is the most effective method of reducing influenza-associated morbidity and mortality. Since the 1940s, the main method of producing influenza vaccines has been an egg-based production process. However, in the event of a pandemic, this method has a significant limitation, as the time lag from strain isolation to final dose formulation and validation is six months. Indeed, production in eggs is a relatively slow process and production yields are both unpredictable and highly variable from strain to strain. In particular, if the next influenza pandemic were to arise from an avian influenza virus, and thus reduce the egg-laying hen population, there would be a shortage of embryonated eggs available for vaccine manufacturing. Although the production of egg-derived vaccines will continue, new technological developments have generated a cell-culture-based influenza vaccine and other more recent platforms, such as synthetic influenza vaccines.
[h=4]KEYWORDS:[/h] cell-culture; synthetic influenza vaccine; vaccination
PMID: 28718786 DOI: 10.3390/vaccines5030018
Free full text